Quest Diagnostics at All-Time High – Apple and New Blood Tests Drive Growth Story
Reading Time: 3 minutes
Apple Health is expected to enable the purchase of lab tests with more than 50 biomarkers directly via the app by 2026. New blood tests for Alzheimer's and cancer open up medically sophisticated diagnostic markets. Partnerships with clinics and automation increase test volumes and profits. Quest raises its annual forecast. Quest Diagnostics (DGX) presents itself as a leader stock in the healthcare sector. On October 29, the stock marked a new all-time high of $253.12. Since the beginning of the year, the increase is around 48%. High demand...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
